BioRestorative Therapies, Inc. Common Stock (NV) (BRTX) — 分析摘要
BioRestorative Therapies, Inc. Common Stock (NV)(BRTX)的市值为5.25百万美元,最近一年的营收同比增长了-10.3%。净利润率为-3959.4%。当前市盈率为-0.5倍。
核心要点
- 营收同比变化-10.3%
- 净利润率-3959.4%
- 市盈率-0.5倍
与SERVICES-MISC HEALTH & ALLIED SERVICES, NEC板块的其他公司相比,BRTX的营收增长为-10.3%,市盈率为-0.5倍。
BioRestorative Therapies, Inc. Common Stock (NV) (BRTX)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -3975.0% — 严重经营亏损
净利率为 -3089.6% — 亏损超过收入(可能含一次性费用)
最新报表显示自由现金流为负。
毛利率为 92.1% — 请核实:除纯软件/IP外极少有企业维持 >90% 毛利率
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
行业
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
员工人数
14
总部
MELVILLE, NY
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。